Ownership
Private
Employees
~10
Therapeutic Areas
RheumatologyCardiovascularDermatology
Stage
Phase 3
Modalities
Small molecule

Eicos Sciences General Information

Phase 3 AURORA trial of CIVI030 (iloprost) for systemic sclerosis was paused due to COVID-19 in March 2020 and resumed in October 2020. Trial targets ~180 patients across 30 US sites.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Chevy Chase, Maryland
United States

Drug Pipeline

iloprost
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Eicos Sciences's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Eicos Sciences Funding

Deal TypeDateAmountStatusStage
Later Stage VCMar 18, 2019$5.0MCompletedPhase 3
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Eicos Sciences's complete valuation and funding history, request access »